BioAxone BioSciences Inc

Closed
Call
Website
90 Canal St Ste 400
Boston, MA 02114
+1 (617) 401-3115
https://bioaxonebio.com

BioAxone BioSciences Inc, based in Boston, MA, is dedicated to the development of innovative drug candidates aimed at improving the lives of patients suffering from neurotrauma and neurovascular disorders. Their portfolio includes an orally available ROCK2 inhibitor licensed to Neurelis, as well as drug candidates BA-210 and BA-434, targeting spinal cord injury and axon regeneration.

The company recently announced significant advancements, including the publication of promising preclinical data for NRL-1049, which shows potential in preserving the blood-brain barrier after injury. BioAxone is also noted for its commitment to research, as evidenced by Dr. Lisa McKerracher's involvement with the National Lab User Advisory Committee for the International Space Station.

Generated from the website

Also at this address

Own this business?
See a problem?

You might also like

Drugs acting on the respiratory system, Biological research

Albireo Pharma, Inc

Founded in 2003, Biodel is a pharmaceutical company that develops novel formulations for therapeutic care solutions. It offers medicines for the treatment of various endocrine disorders, including diabetes and osteoporosis. The company uses VIAdel technology, which enables delivery of endocrine therapeutics into blood through various routes of administration. Biodel also offers VIAject, which is an injectable human insulin product. It provides VIAtab, which is an oral human insulin product. The company offers VIAmass and VIAcal that formulates parathyroid hormone and salmon calcitonin for the treatment of osteoporosis. Additionally, Biodel provides a variety of clinical trial services and organizes various community events.

Viron Inc

Viron Therapeutics Holdings Inc. is a Next-Generation Anti-Viral Technology Company. Viron C1, its first product, a prophylactic against Covid 19, is under FDA review.
Drugs acting on the respiratory system

Elevation Oncology, Inc

Elevation Oncology makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Its lead candidate, seribantumab, which inhibits tumor growth driven by NRG1 fusions, is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.
United States›Massachusetts›Boston›BioAxone BioSciences Inc

Partial Data by Infogroup (c) 2024. All rights reserved.